AzTrials
AzTrials

Bone AtrophyPhase 1Flexi2024NCT06552715

Pilot Study on the Effectiveness of a Flexible Hydroxyapatite-Based Composite for Jaw Bone Regeneration

A Phase 1 study testing Placement of resorbable HAp-based composite in people with Bone Atrophy and Edentulism, run by University of Bologna at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Following a review of the scientific literature, it was found that there are no clinical studies but only in vitro and in vivo studies, which show promising results in terms of bone formation and integration. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Bone Atrophy, Edentulism, Bone Regeneration
What is being tested?
Placement of resorbable HAp-based composite
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteItaly
Study dates
Sep 2024to Sep 2025
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with partially edentulous and atrophic jaws, requiring implant-prosthetic rehabilitation (from 1 to 3 implants), classified as Seibert Class II or III, and needing a GBR bone regeneration intervention with defects not exceeding 7 mm in height
  • Age 18 years or older
  • Obtaining informed consent

Who cannot join

  • Patients who have received radiation therapy to the head and neck with more than 70 Gray.
  • Immunocompromised and immunosuppressed patients.
  • Patients treated with or currently receiving intravenous amino-bisphosphonates.
  • Patients with poor oral hygiene and lack of motivation.
  • Uncontrolled diabetes.
  • Pregnancy or breastfeeding.
Show all 11Show fewer
  • Drug or alcohol dependence.
  • Psychiatric conditions that contraindicate surgical treatment.
  • Limited mouth opening (less than 3.5 cm distance between the two arches in the anterior area).
  • Patients with acute or chronic inflammation/infection at the implant site.
  • Patients referred solely for implant placement.

Trial locations and contacts

1 site in 1 country.

Pietro Felice, MD, DDS, PhD contact

+39 0512088157

pietro.felice@unibo.it

Italy1 site
  • Dental Clinic, Unit of Oral Surgery, University of Bologna

    Bologna, 40125

    Pietro Felice, MD, DDS, PhD, +39 0512088157, pietro.felice@unibo.it

Other trials in Italy

About this study

Official title: Pilot Clinical Study on the Efficacy of a Flexible Hydroxyapatite-Based Composite for the Regeneration of Jaw Bone Defects

Following a review of the scientific literature, it was found that there are no clinical studies but only in vitro and in vivo studies, which show promising results in terms of bone formation and integration. However, it is necessary to evaluate how well the regenerated bone maintains its structural integrity over time, considering masticatory function and real-life biomechanics. Factors such as mechanical load, remodeling dynamics, and interactions with surrounding tissues could influence the long-term stability of the regenerated bone. Additionally, another important aspect to study is the potential complications and adverse effects associated with the use of the flexible HAp-based composite.

Read the detailed description

Following a review of the scientific literature, it was found that there are no clinical studies but only in vitro and in vivo studies, which show promising results in terms of bone formation and integration. However, it is necessary to evaluate how well the regenerated bone maintains its structural integrity over time, considering masticatory function and biomechanics in real-life scenarios. Factors such as mechanical load, remodeling dynamics, and interactions with surrounding tissues could influence the long-term stability of the regenerated bone. Additionally, another important aspect to study is the potential complications and adverse effects associated with the use of the flexible HAp-based composite.

Study Objectives The primary objective is to evaluate the efficacy in terms of regenerated bone volume using the new flexible HAp-based composite in mixed bone defects of the jawbones.

Primary Outcome Measures The volume of regenerated bone will be measured using CBCT scans before device placement, immediately after the surgical procedure, and at 8 months post-procedure. The percentage of regenerated bone obtained compared to the initially planned augmentation, i.e., the mean volume difference, will be calculated before the surgical procedure, immediately after device placement, and at 8 months.

Secondary Objectives These include evaluating intraoperative and postoperative complications occurring at the time of placement or after device placement, assessing the conditions of peri-implant hard and soft tissues, measuring overall patient satisfaction with the treatment, analyzing the correlation between implant survival and various systemic and clinical patient factors, and conducting a histological evaluation of vascularization and new bone formation in samples of regenerated bone taken during implant site preparation.

Secondary Outcome Measures The condition of hard tissues will be assessed based on periapical intraoral radiographs. For soft tissue conditions, for each implant site, peri-implant probing depth (PPD), bleeding on probing (BOP), presence of peri-implant plaque (mPLI), and the amount of keratinized gingiva will be considered at m3, m6, m9, and m12 from implant placement. Any pathological events such as neurological lesions, exposures, infections, inflammation, fractures, or loosening of prosthetic screws, and prosthesis fractures reported in the clinical record during or after device placement and throughout the clinical follow-up will be evaluated as outcomes of intraoperative and postoperative complications at m3, m6, m9, and m12 from device placement. To evaluate overall patient satisfaction, two validated questionnaires will be analyzed: the Oral Health Impact Profile (OHIP-14) and a Patient Satisfaction questionnaire. To assess the correlation between implant survival and certain systemic and clinical patient factors, the following independent variables will be studied: age, gender, smoking status, jaw in which the implants were placed, type of implant, implant length, implant diameter, and compared with implant survival data. Histological and histomorphometric analysis will be conducted on samples of regenerated bone collected during implant site preparation at the passage of the first preparation drill.

Study Plan A total of 20 patients will be included in the study.

Study Design This is a spontaneous, prospective, interventional clinical investigation with post-marketing medical device analysis, enrolling patients with jaw bone atrophy at the Oral Surgery Unit of the Dental Clinic, University of Bologna. Collaboration with the laboratory at the University of Chieti-Pescara, Department of Medical, Oral, and Biotechnological Sciences, is planned. Insurance will be covered by university funds for Oral Surgery.

Study Start Date/Enrollment: After Ethics Committee approval and obtaining corporate clearance Prospective Period: 1 year Total Study Duration: 5 years (including individual follow-ups and data processing)

Study Population Inclusion Criteria Patients with partially edentulous and atrophic jaws, requiring implant-prosthetic rehabilitation (from 1 to 3 implants), classified as Seibert Class II or III, and needing a GBR bone regeneration intervention with defects not exceeding 7 mm in height. Patients must be 18 years or older and must provide informed consent.

Exclusion Criteria General contraindications to implant surgery. Patients who have received head and neck irradiation of more than 70 Gray. Immunocompromised and immunosuppressed patients. Patients treated or under treatment with intravenous amino-bisphosphonates. Patients with poor oral hygiene and motivation. Uncontrolled diabetes. Pregnancy or breastfeeding. Drug or alcohol dependency. Psychiatric conditions that contraindicate surgical treatment. Limited mouth opening (less than 3.5 cm between the two arches in the anterior region). Patients with acute or chronic inflammation/infection at the implant site. Patients referred solely for implant placement.

Medical Device Under Study The study focuses on a bio-composite bone substitute based on hydroxyapatite (Flexi-Oss, Medical Inventi S.A., Lublin, Poland). This is a biphasic material comprising hydroxyapatite and a polymer component.

Statistical Methods Sample Size The mean regenerated bone volume using a semi-occlusive CAD/CAM titanium device from a previous study was 1524 mm³. Considering an estimate of 1380 mm³ of regenerated bone using the hydroxyapatite-based bio-composite bone substitute, with a standard deviation of 200 mm³, a significance level (alpha) of 0.05, and a statistical power of 80%, using the two-sided Z test, it was determined that 16 patients need to be enrolled. Considering a potential dropout rate of 20%, the number of patients to be included in the study has been increased to 20.

Being tested
Placement of resorbable HAp-based composite
Keywords
bone regeneration, dental implants, jaws atrophy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Placement of resorbable HAp-based compositeDevice

    The resorbable HAp-based composite device will be immersed in a saline solution for 15 minutes, allowing it to transition from a rigid state to a flexible and deformable one (Fig. 1). Subsequently, the device will be shaped appropriately on the resin model, ensuring proper placement within the bone defect to be regenerated. Patients will receive antibiotic prophylaxis of 1 g amoxicillin, 1 hour before the procedure (or 300 mg clindamycin in case of penicillin allergy). Before the surgical procedure, patients will rinse with 2% chlorhexidine for one minute to reduce the bacterial load in the oral cavity. For the surgical procedure, under local anesthesia with Articaine and Adrenaline 1:100000, mucoperiosteal flaps will be raised. The pre-shaped resorbable device will then be adapted to the defect and fixed with osteosynthesis screws, used according to clinical practice for this type of intervention. Finally, the flaps will be sutured to ensure primary intention closure.

Study groups in NCT06552715
Study groupRoleWhat they receive
Treatment with hydroxyapatite-based compositeExperimentalPatients with partially edentulous and atrophic jaws, requiring implant-prosthetic rehabilitation (from 1 to 3 implants), classified as Seibert Class II or III, and needing a GBR bone regeneration intervention with defects not exceeding 7 mm in height. Patients must be 18 years or older and must provide informed consent.
Receives: Device: Placement of resorbable HAp-based composite

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Regenerated Bone Volume

    he volume of regenerated bone will be measured using CBCT scans before device placement, immediately after the surgical procedure, and at 8 months post-procedure. The percentage of regenerated bone obtained compared to the initially planned augmentation, i.e., the mean volume difference, will be calculated before the surgical procedure, immediately after device placement, and at 8 months. It is specified that CBCT scans and the procedure are performed as part of routine clinical practice.

    Measured: From the treatment and after 8 months,

Secondary outcomes (8)
  1. Complications

    Any pathological events such as neurological lesions, exposures or infections of the placed medical device, inflammation, fractures or loosening of prosthetic screws, prosthesis fracture, etc., reported in the clinical record and occurring during or after implant placement and throughout the clinical follow-up (m1; m3; m6; m8; and m12 from the surgical placement of the device) will be evaluated as outcomes of intraoperative and postoperative complications.

    Measured: Months 1, 3, 6, 8, and 12.

  2. Patient Satisfaction

    To evaluate the overall satisfaction of patients undergoing the treatment, a validated questionnaire, the Oral Health Impact Profile (OHIP-14), is completed by patients during follow-up visits. The same questionnaire will be administered to patients one month after the surgical procedure and eight months after the procedure. OHIP is a 14-item questionnaire.

    Measured: At 1 month and 9 months after treatment

  3. Correlation between implant survival and certain systemic and clinical patient factors

    The following independent variables will be studied: age, gender, smoking status, jaw in which the implants were placed, type of implant, implant length, implant diameter, and compared with implant survival data (m6, m12, and 3 years)

    Measured: After Treatment for 3 years

  4. Histological analysis

    Histological analysis on samples of regenerated bone collected during the preparation of the implant site, specifically during the passage of the first preparation drill. Paraffin sections will be cut at 4 µm, fixed in formalin, and mounted on slides treated with 3-aminopropyltriethoxysilane. The sections will then undergo immunostaining for blood vessels using antibodies against CD31, VEGF, and KDR epitopes.The criteria established by Weidner and Folkman will be used to identify blood vessels in the immunostained sections. Specifically, positively stained endothelial cells or groups of endothelial cells, regardless of shape and size, that are clearly separated from adjacent blood vessels or other connective tissues, will be counted as blood vessels. Vascular nodules, although usually present, will not be considered a definition of a blood vessel, and red blood cells will not be used to calculate the vascular lumen.

    Measured: 8 months after device placement.

  5. Hard Tissues Conditions

    The condition of hard tissues is assessed based on periapical intraoral radiographs, taken using the parallel technique before and after the preservation procedure, at the time of implant placement, at the initial loading, and at the final prosthetic loading and various follow-ups.

    Measured: At months: 3, 6, 12 and 3 years after treatment

  6. Peri-implant probing depth (PPD) in mm

    The condition of soft tissues is evaluated using periodontal indices and recorded in the clinical record: using a periodontal probe, the peri-implant probing depth (PPD) will be evaluated in millimiters, and the are measured for each implant site (at m3, m6, m12, and 3 years post-implant placement).

    Measured: At months: 3, 6, 12 and 3 years after treatment

  7. bleeding on probing (BOP),

    Using a periodontal probe, the presence of bleeding around the implants will be recorded in the clinical record.

    Measured: At months: 3, 6, 12 and 3 years after treatment

  8. Amount of keratinized gingiva

    Using a periodontal probe, the amount of keratinized gingiva will be assessed in millimiters and recorded in clinical record.

    Measured: At months: 3, 6, 12 and 3 years after treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Aug 2024
  2. Study startSep 2024 (estimated)
  3. Primary completionApr 2025 (estimated)
  4. Study completionSep 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06552715
Sponsor's protocol ID
PG0091421_2024
Acronym
Flexi2024
Status last verified
Aug 2024
First submitted
7 Aug 2024
Last updated
14 Aug 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Original articles in international journals

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Placement of resorbable HAp-based composite in people with Bone Atrophy and Edentulism, run by University of Bologna at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 14 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Pietro Felice, MD, DDS, PhD (+39 0512088157, pietro.felice@unibo.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Regenerated Bone Volume (time frame: From the treatment and after 8 months,). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in